National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)
National Institutes of Health
Sign in and complete your Funding Passport to see whether you qualify — a transparent, rule-based verdict, not a black box.
Sign InAbout this opportunity
Reissue of PAR-20-119. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, substance use disorders (SUDs) or alcohol use disorder (AUD), and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. This FOA supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. Projects seeking support for a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies should consider the companion U01 FOA.
Required documents
The official source lists no specific documents here — confirm requirements before applying.
Source & verification trail
- Official source
- U.S. Federal Government (Grants.gov) ↗
- First retrieved
- November 20, 2026
- Last verified
- November 20, 2026
- Content fingerprint
5fd3777aaf3949ed…